Search

Your search keyword '"Ramnath N"' showing total 78 results

Search Constraints

Start Over You searched for: Author "Ramnath N" Remove constraint Author: "Ramnath N" Topic lung neoplasms Remove constraint Topic: lung neoplasms
78 results on '"Ramnath N"'

Search Results

1. Impact of lung cancer screening on stage migration and mortality among the national Veterans Health Administration population with lung cancer.

2. Pneumonitis After Chemoradiotherapy and Adjuvant Durvalumab in Stage III Non-Small Cell Lung Cancer.

3. Barriers to Timely Lung Cancer Care in Early Stage Non-Small Cell Lung Cancer and Impact on Patient Outcomes.

4. Modeling Molecular Pathogenesis of Idiopathic Pulmonary Fibrosis-Associated Lung Cancer in Mice.

5. A Phase II Trial of Pevonedistat and Docetaxel in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer.

6. Circulating tumor cells reveal early predictors of disease progression in patients with stage III NSCLC undergoing chemoradiation and immunotherapy.

7. Class II HLA-DRB4 is a predictive biomarker for survival following immunotherapy in metastatic non-small cell lung cancer.

8. Neoadjuvant Versus Adjuvant Systemic Therapy for Early-Stage Non-Small Cell Lung Cancer: The Changing Landscape Due to Immunotherapy.

9. The Lung Microbiome in Carcinogenesis and Immunotherapy Treatment.

10. Adoption of Extended-Interval Dosing of Single-Agent Pembrolizumab and Comparative Effectiveness vs Standard Dosing in Time-to-Treatment Discontinuation.

11. Case report: A persistently expanded T cell response in an exceptional responder to radiation and atezolizumab for metastatic non-small cell lung cancer.

12. De-escalating adjuvant durvalumab treatment duration in stage III non-small cell lung cancer.

13. Prognostic and Predictive Role of PD-L1 Expression in Stage III Non-small Cell Lung Cancer Treated With Definitive Chemoradiation and Adjuvant Durvalumab.

14. Cellular engagement and interaction in the tumor microenvironment predict non-response to PD-1/PD-L1 inhibitors in metastatic non-small cell lung cancer.

15. Timing of Adjuvant Durvalumab Initiation Is Not Associated With Outcomes in Stage III Non-small Cell Lung Cancer.

16. Prognostic and predictive value of neutrophil-to-lymphocyte ratio with adjuvant immunotherapy in stage III non-small-cell lung cancer.

17. Bone Metastases, Skeletal-Related Events, and Survival in Patients With Metastatic Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors.

18. A Pilot Study of Atezolizumab Plus Hypofractionated Image Guided Radiation Therapy for the Treatment of Advanced Non-Small Cell Lung Cancer.

19. Simultaneous Single Cell Gene Expression and EGFR Mutation Analysis of Circulating Tumor Cells Reveals Distinct Phenotypes in NSCLC.

20. Impact of Staging With Positron-emission Tomography (PET) and Comorbidities on Management and Survival of American Veterans With Stage I-III Non-Small Cell Lung Cancer.

21. Radiation-induced lung toxicity in non-small-cell lung cancer: Understanding the interactions of clinical factors and cytokines with the dose-toxicity relationship.

22. Effect of Midtreatment PET/CT-Adapted Radiation Therapy With Concurrent Chemotherapy in Patients With Locally Advanced Non-Small-Cell Lung Cancer: A Phase 2 Clinical Trial.

23. Poor Prognosis Indicated by Venous Circulating Tumor Cell Clusters in Early-Stage Lung Cancers.

24. Clinical Determinants of Durable Clinical Benefit of Pembrolizumab in Veterans With Advanced Non-Small-Cell Lung Cancer.

25. Expanded Circulating Tumor Cells from a Patient with ALK-Positive Lung Cancer Present with EML4-ALK Rearrangement Along with Resistance Mutation and Enable Drug Sensitivity Testing: A Case Study.

26. Oncogenic Potential of CYP24A1 in Lung Adenocarcinoma.

27. Mechanisms of immune evasion and current status of checkpoint inhibitors in non-small cell lung cancer.

28. Pulmonary venous blood sampling significantly increases the yield of circulating tumor cells in early-stage lung cancer.

29. A Novel Serum 4-microRNA Signature for Lung Cancer Detection.

30. MAP3K3 expression in tumor cells and tumor-infiltrating lymphocytes is correlated with favorable patient survival in lung cancer.

32. Expansion of CTCs from early stage lung cancer patients using a microfluidic co-culture model.

33. KRAS-G12C mutation is associated with poor outcome in surgically resected lung adenocarcinoma.

34. Effects of cigarette smoking on metabolism and effectiveness of systemic therapy for lung cancer.

35. A MicroRNA cluster at 14q32 drives aggressive lung adenocarcinoma.

36. Epigenetic regulation of vitamin D metabolism in human lung adenocarcinoma.

37. Phase II study of perioperative chemotherapy with cisplatin and pemetrexed in non-small-cell lung cancer.

38. A phase I/II pharmacokinetic and pharmacogenomic study of calcitriol in combination with cisplatin and docetaxel in advanced non-small-cell lung cancer.

39. Treatment of stage III non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.

40. Characterization of vitamin D receptor (VDR) in lung adenocarcinoma.

41. Changes in global function and regional ventilation and perfusion on SPECT during the course of radiotherapy in patients with non-small-cell lung cancer.

42. Phase II trial of sunitinib maintenance therapy after platinum-based chemotherapy in patients with extensive-stage small cell lung cancer.

43. Vitamin D and lung cancer.

44. CYP24A1 is an independent prognostic marker of survival in patients with lung adenocarcinoma.

45. Semiquantification and classification of local pulmonary function by V/Q single photon emission computed tomography in patients with non-small cell lung cancer: potential indication for radiotherapy planning.

46. Phase II trial of imatinib maintenance therapy after irinotecan and cisplatin in patients with c-Kit-positive, extensive-stage small-cell lung cancer.

47. EphA2 mutation in lung squamous cell carcinoma promotes increased cell survival, cell invasion, focal adhesions, and mammalian target of rapamycin activation.

48. A phase II study of dasatinib in patients with chemosensitive relapsed small cell lung cancer (Cancer and Leukemia Group B 30602).

49. Ethnic differences and functional analysis of MET mutations in lung cancer.

50. Semiquantitative visual approach to scoring lung cancer treatment response using computed tomography: a pilot study.

Catalog

Books, media, physical & digital resources